Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Zambon

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Giornale Italiano Di Cardiologia (2006)|June 18, 2016
[Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies]Alberto Zambon
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|June 11, 2020
The long-term safety and efficacy of fibrates in patients with hypertriglyceridemia: Real-life data from a lipid clinic cohortAlberto Zambon
Internal and Emergency Medicine|October 20, 2011
Residual cardiovascular risk in secondary preventionAlberto Zambon
Internal and Emergency Medicine|December 16, 2014
The new ACC/AHA guidelines on the treatment of dyslipidemia: consAlberto Zambon
Diabetes & Vascular Disease Research|November 21, 2007
The role of fenofibrate in clinical practiceAlberto Zambon, Kenneth Cusi
Giornale Italiano Di Cardiologia (2006)|July 18, 2017
[The FOURIER study]Furio Colivicchi, Alberto Zambon
Giornale Italiano Di Cardiologia (2006)|September 9, 2008
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]Alberto Zambon, Michela Marchiori, Enzo Manzato
Nature Clinical Practice. Cardiovascular Medicine|July 17, 2008
Fibrates and future PPARalpha agonists in the treatment of cardiovascular diseaseBart Staels, Michel Maes, Alberto Zambon
Giornale Italiano Di Cardiologia (2006)|June 18, 2016
[Hypercholesterolemia and cardiovascular risk: advantages and limitations of current treatment options]Claudio Cimminiello, Alberto Zambon, Hernan Polo Friz
Current Atherosclerosis Reports|December 26, 2025
Fibrates : Do They Still Have a Role in Therapy in 2025?Angela Pirillo, Alberto Zambon, Alberico L Catapano
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Giornale Italiano Di Cardiologia (2006)|June 18, 2016
[Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies]Alberto Zambon
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|June 11, 2020
The long-term safety and efficacy of fibrates in patients with hypertriglyceridemia: Real-life data from a lipid clinic cohortAlberto Zambon
Internal and Emergency Medicine|October 20, 2011
Residual cardiovascular risk in secondary preventionAlberto Zambon
Internal and Emergency Medicine|December 16, 2014
The new ACC/AHA guidelines on the treatment of dyslipidemia: consAlberto Zambon
Diabetes & Vascular Disease Research|November 21, 2007
The role of fenofibrate in clinical practiceAlberto Zambon, Kenneth Cusi
Giornale Italiano Di Cardiologia (2006)|July 18, 2017
[The FOURIER study]Furio Colivicchi, Alberto Zambon
Giornale Italiano Di Cardiologia (2006)|September 9, 2008
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]Alberto Zambon, Michela Marchiori, Enzo Manzato
Nature Clinical Practice. Cardiovascular Medicine|July 17, 2008
Fibrates and future PPARalpha agonists in the treatment of cardiovascular diseaseBart Staels, Michel Maes, Alberto Zambon
Giornale Italiano Di Cardiologia (2006)|June 18, 2016
[Hypercholesterolemia and cardiovascular risk: advantages and limitations of current treatment options]Claudio Cimminiello, Alberto Zambon, Hernan Polo Friz
Current Atherosclerosis Reports|December 26, 2025
Fibrates : Do They Still Have a Role in Therapy in 2025?Angela Pirillo, Alberto Zambon, Alberico L Catapano
Pageof 10